by David Wallace What does precision medicine look like in MPNs? Can it be used to diagnose, prognosticate and treat patients? Discover information on driver mutations, symptom burden scoring and how it is used in some clinical visits. Learn more as Dr. Naveen Pemmaraju, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University […]
New MPN Drug Treatments in Development
by David Wallace What are some of the latest combination drug treatments in development for MPN? Find out the latest on combination add-on strategies to JAK inhibitors and other new agents. Two combination therapies for Myelofibrosis look promising as they move into phase 3 clinical trials. They include adding CPI-0610 (a bromodomain, BET, inhibitor) and […]
Clinical Trial Update on Emerging MPN Treatments
by David Wallace Find out the latest news on Ropeginterferon and PTG-300 for treating polycythemia vera, as well as the most promising new treatments for myelofibrosis. What’s the clinical significance of the Allele Burden (AB)? Are there common elements between COVID-19 and MPN…should you get the vaccine? Learn more as Dr. Srdan Verstovsek, Professor, Department of […]
ASH 2014 Series Coverage
by David Wallace PV Reporter covering the American Society of Hematology (ASH) 2014 conference in a series format For me personally, highlights go beyond the research that was presented (ASH 2014 Outside the Box, addresses that in detail). It was about meeting friends…old and new (in person), attending the MPN Heroes Awards Presentation, the excitement […]
ASH 2013 News on MPNs
This update is provided by the MPN Research Foundation This year’s American Society of Hematology (ASH) meeting provided a bittersweet update on the progress of JAK inhibition therapy in the MPNs. As many readers already know, the Sanofi JAK inhibitor, which had completed Phase 3 trials and was well on its way to the FDA […]
